RankAlpha logo
Back to Rankings

HALO

Halozyme TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The earnings follow-up supports a still-positive post-print read: Halozyme beat the Zacks-tracked Q1 EPS and revenue figures cited by AP, reiterated full-year guidance, and paired that with a larger buyback, which together argue that royalty growth and margin conversion remain intact.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Forward growth still relies on development-stage programs converting into approvals and commercial uptake over several years, so timeline slips can defer the next royalty wave.
Momentum
50
Value
66
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $79.00 · Bull $88.00 · Bear $60.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $83.90
Why
Momentum50 · Δ7d -25.4
Value66 · Δ7d -0.2
Sentiment45 · Δ7d -4.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
50
26% active weight
Current posture
7d trendSoftening
Δ7d
-25.4
Δ21d
+0.1
Value
66
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.1
Sentiment
45
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.3
Δ21d
-3.8
Why this grade

Composite grade B. Momentum 49.9 / Value 66.2 / Sentiment 44.9

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$9.32B
Beta
0.97
Shares Out
118.61M
P/E (TTM)
15.0
P/S (TTM)
6.74
P/FCF (TTM)
13.90
Rev YoY
+42.2%
EPS YoY
+31.0%
Gross Margin
+76.9%
Op Margin
+59.3%
Net Debt
$2.03B
Current Ratio
2.76
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology